Rofecoxib (CAS 162011-90-7) Suppliers and Product Information

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used as an anti-inflammatory and ***gesic agent. It was marketed from 1999 to 2004 for the treatment of osteoarthritis, acute pain, and primary dysmenorrhea. The drug was withdrawn due to increased risks of heart attack and stroke associated with long-term use.

Rofecoxib is well-absorbed orally, with peak plasma levels reached within 2-3 hours of dosing. It has a bioavailability of approximately 93% and is primarily excreted in urine (72%) as metabolites, with less than 1% excreted unchanged. The drug is metabolized mainly by cytosolic enzymes, with minimal involvement of the cytochrome P450 system.

Frequently Asked Questions about Rofecoxib

Q: What was Rofecoxib used for?

A: Rofecoxib was primarily used for the treatment of osteoarthritis, management of acute pain in ***s, and treatment of primary dysmenorrhea.

Q: Why was Rofecoxib withdrawn from the market?

A: Rofecoxib was withdrawn in 2004 due to concerns about an increased risk of heart attack and stroke associated with long-term use.

Q: What are the common side effects of Rofecoxib?

A: Common side effects include mild to moderate gastrointestinal irritation, diarrhea, nausea, vomiting, dyspepsia, abdominal pain, lower extremity edema, and hypertension.

Q: How does Rofecoxib work?

A: Rofecoxib is a selective COX-2 inhibitor, which reduces inflammation and pain by blocking the production of inflammatory prostaglandins without affecting the protective prostaglandins in the stomach and kidneys.

Q: What was the recommended dosage for Rofecoxib?

A: For osteoarthritis, the recommended starting dose was 12.5 mg once daily, with a maximum recommended dose of 25 mg daily. For acute pain and primary dysmenorrhea, the recommended initial dose was 50 mg once daily, with use not studied for more than 5 days in pain management.